Zobrazeno 91 - 100
of 233
pro vyhledávání: '"Richard F. Little"'
Autor:
Wyndham H. Wilson, Kristie A. Blum, Brad S. Kahl, Michael E. Williams, Sonali M. Smith, John P. Leonard, Grzegorz S. Nowakowski, Lawrence Baizer, Laurie H. Sehn, David G. Maloney, Richard F. Little, Jonathan W. Friedberg
Publikováno v:
Journal of the National Cancer Institute. 108(12)
Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL
Autor:
Mark N. Polizzotto, Elaine S. Jaffe, Vickie Marshall, Seth M. Steinberg, Richard F. Little, Victoria Wang, Karen Aleman, Giovanna Tosato, Stefania Pittaluga, Kathleen M. Wyvill, Corina Millo, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan, Irini Sereti
BACKGROUND Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD). Recently a KSHV-associated inflammatory cytokine syndrome (KICS) distinct from KSHV-MCD was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aed796309b28ae7ecab46ac41fe9875
https://europepmc.org/articles/PMC4772848/
https://europepmc.org/articles/PMC4772848/
Autor:
Xiaonan Xue, Michele Spina, Christian Hoffmann, Dan Wang, Richard F. Little, Jitesh Joshi, Lionel Galicier, Joseph A. Sparano, Kieron Dunleavy, Nicolas Mounier, José-Tomás Navarro, Wyndham H. Wilson, Josep-Maria Ribera, Ariela Noy, Stefan K. Barta
Publikováno v:
British journal of haematology. 173(6)
Central nervous system (CNS) involvement is reportedly more common in acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). We describe factors and outcomes associated with CNS involvement at baseline (CNS(B) ) and relapse (CNS(R) ) in 8
Autor:
Richard F. Little, Howard Streicher
Publikováno v:
Blood. 130:107-108
Given the limited treatment options for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and the success of programmed death 1 (PD-1) blockade in classical Hodgkin lymphoma (cHL) patients, anti-PD-1 monoclonal anti
Autor:
Jonathan W. Friedberg, Brad S. Kahl, Brian K. Link, Bayard L. Powell, Mark Roschewski, Christopher Melani, Wyndham H. Wilson, Deepa Jagadeesh, Ariela Noy, Wahid Hanna, Nancy L. Bartlett, Seth M. Steinberg, David Peace, Jeremy S. Abramson, Kieron Dunleavy, Michelle A. Fanale, Philip J. Bierman, Andrea Nicole Lucas, Samir Parekh, Richard F. Little, Peter R. Watson
Publikováno v:
Hematological Oncology. 35:133-134
Autor:
Lisa M. McShane, Richard F. Little
Publikováno v:
Blood. 128:2747-2748
In this issue of Blood , [Kwok and colleagues][1] have provided a wealth of retrospective clinical data that greatly expands our appreciation for the prognostic importance of flow-cytometric residual disease measurement across a spectrum of clinical
Autor:
Lakshmi Rajdev, Elizabeth Y. Chiao, Shelly Lensing, Richard F. Little, Dirk Dittmer, Mark H. Einstein, Missak Haigentz, Joseph A. Sparano, Ronald T. Mitsuyasu
Publikováno v:
Journal of Clinical Oncology. 36:TPS2597-TPS2597
Autor:
Rashmi Chugh, Laurence H. Baker, Joseph M. Unger, Richard F. Little, Jessica P. Hwang, Dawn L. Hershman, Rohit Loomba, Scott D. Ramsey, Kathryn B. Arnold, Monica A. Konerman
Publikováno v:
Journal of Clinical Oncology. 36:6600-6600
6600Background: Universal screening of newly diagnosed cancer patients for HIV, HBV and HCV viruses is not routine in oncology practice. Amid concerns about viral reactivation and adverse outcomes ...
Autor:
Wyndham H. Wilson, Kieron Dunleavy, Seth M. Steinberg, Nicole Grant, Richard F. Little, Robert Yarchoan, Jorge A. Carrasquillo, Elaine S. Jaffe, Alan S. Wayne, Stefania Pittaluga
Publikováno v:
Blood. 115:3017-3024
This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (S
Autor:
Elizabeth Y. Chiao, Missak Haigentz, Shelly Lensing, Dirk P. Dittmer, Ronald T. Mitsuyasu, Joseph A. Sparano, Lakshmi Rajdev, Howard Streicher, Mark H. Einstein, Richard F. Little
Publikováno v:
Journal of Clinical Oncology. 36:TPS44-TPS44
TPS44 Background: Immune checkpoint blockade (ICB) using agents that target the priming phase (i.e. CTLA-4) and effector phase (e.g. PD-1) of host immunity, used individually or in combination, has emerged as a therapeutic strategy for cancers. Howev